Journal of women's health
-
Journal of women's health · Jul 2013
Comparative StudyHealth disparities among sexual minority women veterans.
Lesbian and bisexual (i.e., sexual minority) identity is more common among women veterans than among male veterans. Unique health issues have been identified among women veterans and among sexual minority women, but little is known about women who are both sexual minorities and veterans. This study aimed to compare demographic and health information from sexual minority women veterans with sexual minority women non-veterans and heterosexual women veterans. ⋯ Results suggest sexual minority women veterans may experience unique health disparities relevant to provision of care in both Veterans Affairs (VA) and non-VA healthcare systems. Future research requires availability of data that include sexual minority status.
-
Journal of women's health · Jul 2013
Comparative StudyDisparities in women's health across a generation: a mother-daughter comparison.
The U.S. Centers for Disease Control and Prevention has set national goals to eliminate health disparities by race, sex, and socioeconomic status. Progress in meeting these goals has been mixed. This paper provides a different view on the evolving health of U.S. women by examining a sample of daughters and their mothers. ⋯ Health deterioration across generations in both races suggests that much work is needed to meet Healthy People 2020 goals of health equity.
-
Journal of women's health · Jul 2013
Comparative StudyAssociation of breast arterial calcifications, metabolic syndrome, and the 10-year coronary heart disease risk: a cross-sectional case-control study.
Breast arterial calcifications (BACs) are common but underreported findings on mammography. The purpose of this study was to examine the relationship between BACs, metabolic syndrome (MS), and coronary heart disease (CHD) risk. ⋯ Findings of BACs on mammogramy are associated with an increased risk of MS and the calculated risk of CHD in women older than 40 years of age.
-
Journal of women's health · Jul 2013
Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
Biological sex differences may contribute to differential treatment outcomes for therapeutic products. This study tracks women's participation in late-phase clinical trials (LPCTs), where efficacy and safety of drugs and biologics are evaluated, of new molecular entity (NME) drugs and biologics approved by the U.S. Food and Drug Administration (FDA) in 2007-2009. Furthermore, presentations of sex-based analyses were assessed from the FDA reviews. ⋯ Women's participation in LPCTs averaged 43% for NDAs and 57% for BLAs in 2007-2009 and varied widely by indication. As a comparison, the 2001 U.S. Government Accountability Office (GAO) reported 52% of women's participation for drug clinical trials in1998-2000 and an FDA study reported 45% for BLAs approved from 1995 to 1999. This study showed that sex-analysis of both safety and efficacy in NDA has increased to 74% since the GAO report of 72%, while those for BLAs increased to 64% from 37% reported for therapeutic biologics approved in 1995-1999. Knowledge of disease prevalence and participation in clinical trials provides an understanding of recruitment and retention patterns of patients in these trials.
-
To estimate the demand for women's health care by 2020 using today's national utilization standards. ⋯ Using today's national norms of ob-gyn related services, a modest growth in women's health care demands is estimated by 2020 that will require a larger provider workforce.